Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to 18F-fluorodeoxyglucose positron emission tomography (FDGPET). Discordance between size criteria and metabolic criteria has been reported in liver gastrointestinal stromal tumors, hepatomas, and renal cell carcinomas after dramatic responses with targeted therapies such as imatinib, sorafenib, and sunitinib. However, this discordance has been rarely reported in liver metastases of gastric adenocarcinoma when treated with conventional chemotherapy.
Abstract
We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to 18F-fluorodeoxyglucose positron emission tomography (FDGPET). Discordance between size criteria and metabolic criteria has been reported in liver gastrointestinal stromal tumors, hepatomas, and renal cell carcinomas after dramatic responses with targeted therapies such as imatinib, sorafenib, and sunitinib. However, this discordance has been rarely reported in liver metastases of gastric adenocarcinoma when treated with conventional chemotherapy.
참고문헌 (8)
- Abou-Alfa GK, "Phase II study of sorafenib in patients with advanced hepatocellular carcinoma", J Clin Oncol, 24, pp.4293~4300 (2006)
- Benjamin RS, "We should desist using RECIST, at least in GIST", J Clin Oncol, 25, pp.1760~1764 (2007)
- Choi H, "Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria", J Clin Oncol, 25, pp.1753~1759 (2007)
- Motzer RJ, "Targeted therapy for metastatic renal cell carcinoma", J Clin Oncol, 24, pp.5601~5608 (2006)
- Antoch G, "Comparison of PET, CT, and dual-modality PET", CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors, 2004, pp.45, 357~365
- Goerres GW, "The value of PET, CT and in-line PET", CT in patients with gastrointestinal stromal tumours: longterm outcome of treatment with imatinib mesylate, 2005, pp.32, 153~162
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Stroobants S, "18FDGPositron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)", Eur J Cancer, 39, pp.2012~2020 (2003)